Office of the Director, National Institutes of Health; Notice of Meeting, 29126-29127 [2018-13419]
Download as PDF
<![CDATA[
29126
Federal Register / Vol. 83, No. 121 / Friday, June 22, 2018 / Notices
Dated: June 19, 2018.
Natasha M. Copeland,
Program Analyst, Office of Federal Advisory
Committee Policy.
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
[FR Doc. 2018–13417 Filed 6–21–18; 8:45 am]
National Institute of Allergy and
Infectious Diseases; Notice of Closed
Meetings
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Allergy and
Infectious Diseases; Notice of Closed
Meeting
daltland on DSKBBV9HB2PROD with NOTICES
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The contract proposals and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the contract
proposals, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Allergy and Infectious Diseases Special
Emphasis Panel; Source Selection Meeting
for NIAID IRF at Fort Detrick.
Date: July 3, 2018.
Time: 1:00 p.m. to 3:00 p.m.
Agenda: To review and evaluate contract
proposals.
Place: National Institutes of Health, 5601
Fishers Lane, Rockville, MD 20892
(Telephone Conference Call).
Contact Person: Dharmendar Rathore,
Ph.D., Senior Scientific Review Officer,
Scientific Review Program, Division of
Extramural Activities, Room 3G30, National
Institutes of Health/NIAID, 5601 Fishers
Lane, MSC 9834, Bethesda, MD 20892–9834,
240–669–5058, rathored@mail.nih.gov.
This notice is being published less than 15
days prior to the meeting due to the urgent
need to meet timing limitations imposed by
the intramural research review cycle.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.855, Allergy, Immunology,
and Transplantation Research; 93.856,
Microbiology and Infectious Diseases
Research, National Institutes of Health, HHS)
Dated: June 19, 2018.
Natasha M. Copeland,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2018–13415 Filed 6–21–18; 8:45 am]
BILLING CODE 4140–01–P
VerDate Sep<11>2014
17:16 Jun 21, 2018
Jkt 244001
National Institutes of Health
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Allergy and Infectious Diseases, Special
Emphasis Panel, Integrated Preclinical/
Clinical AIDS Vaccine Development
Program, (IPCAVD) (U19).
Date: July 12–13, 2018.
Time: 9:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 5601
Fishers Lane, Rockville, MD 20892
(Telephone Conference Call).
Contact Person: J. Bruce Sundstrom, Ph.D.,
Scientific Review Officer, Scientific Review
Program, Division of Extramural Activities,
Room 3G11A, National Institutes of Health/
NIAID, 5601 Fishers Lane, MSC 9823,
Bethesda, MD 20892–9823, 240–669–5045,
sundstromj@niaid.nih.gov.
Name of Committee: National Institute of
Allergy and Infectious Diseases Special
Emphasis Panel, NIAID Investigator Initiated
Program Project Applications (P01).
Date: July 12, 2018.
Time: 1:00 p.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 5601
Fishers Lane, Rockville, MD 20892
(Telephone Conference Call).
Contact Person: Priti Mehrotra, Ph.D.,
Chief, Immunology Review Branch, Scientific
Review Program, Division of Extramural
Activities, Room #3G40, National Institutes
of Health/NIAID, 5601 Fishers Lane, MSC
9823, Bethesda, MD 20892–7616, 240–669–
5066, pmehrotra@niaid.nih.gov.
Name of Committee: National Institute of
Allergy and Infectious Diseases Special
Emphasis Panel, NIAID Investigator Initiated
Program Project Applications (P01).
Date: July 13, 2018.
Time: 10:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 5601
Fishers Lane, Rockville, MD 20892
(Telephone Conference Call).
PO 00000
Frm 00039
Fmt 4703
Sfmt 4703
Contact Person: Priti Mehrotra, Ph.D.,
Chief, Immunology Review Branch, Scientific
Review Program, Division of Extramural
Activities, Room #3G40, National Institutes
of Health/NIAID, 5601 Fishers Lane, MSC
9823, Bethesda, MD 20892–7616, 240–669–
5066, pmehrotra@niaid.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.855, Allergy, Immunology,
and Transplantation Research; 93.856,
Microbiology and Infectious Diseases
Research, National Institutes of Health, HHS)
Dated: June 19, 2018.
Natasha M. Copeland,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2018–13414 Filed 6–21–18; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Office of the Director, National
Institutes of Health; Notice of Meeting
Pursuant to section 10(a) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of a meeting of the Office
of AIDS Research Advisory Council.
The meeting will be open to the
public, with attendance limited to space
available. Individuals who plan to
attend and need special assistance, such
as sign language interpretation or other
reasonable accommodations, should
notify the Contact Person listed below
in advance of the meeting.
Name of Committee: Office of AIDS
Research Advisory Council.
Date: July 12, 2018.
Time: 11:00 a.m. to 12:30 p.m.
Agenda: Report to the OAR Director;
Overview of key upcoming OAR activities;
Updates of the HHS HIV/AIDS Treatment
and Prevention Guidelines.
Place: National Institutes of Health, 5601
Fishers Lane, Bethesda, MD 20892 (Virtual
Meeting).
Contact Person: Paul A. Sato, Medical
Officer, Office of AIDS Research, Office of the
Director, NIH, 5601 Fishers Lane, Room 2E62
Rockville, MD 20852, 240–480–2330,
paul.sato@nih.gov.
Any interested participants are encouraged
to join this meeting at the weblink provided,
at least 30 minutes prior to the scheduled
start time. Information is also available on
the Institute’s/Center’s home page:
www.oar.nih.gov, where an agenda and any
additional information for the meeting will
be posted when available.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.14, Intramural Research
Training Award; 93.22, Clinical Research
Loan Repayment Program for Individuals
from Disadvantaged Backgrounds; 93.232,
Loan Repayment Program for Research
Generally; 93.39, Academic Research
E:\FR\FM\22JNN1.SGM
22JNN1
Federal Register / Vol. 83, No. 121 / Friday, June 22, 2018 / Notices
Enhancement Award; 93.936, NIH Acquired
Immunodeficiency Syndrome Research Loan
Repayment Program; 93.187, Undergraduate
Scholarship Program for Individuals from
Disadvantaged Backgrounds, National
Institutes of Health, HHS)
Dated: June 19, 2018.
Natasha M. Copeland,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2018–13419 Filed 6–21–18; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Prospective Grant of an Exclusive
Patent License: Methods of Modulating
Erythropoiesis With Arginine
Vasopressin Receptor 1B Molecules
AGENCY:
National Institutes of Health,
HHS.
ACTION:
Notice.
The National Institute of
Dental and Craniofacial Research, an
institute of the National Institutes of
Health, Department of Health and
Human Services, is contemplating the
grant of an Exclusive Patent License to
practice the inventions embodied in the
Patent Applications listed in the
Supplementary Information section of
this notice to ERYTHRYx Therapeutics,
located in Los Angeles, California.
DATES: Only written comments and/or
applications for a license which are
received by the Office of Technology
Transfer and Innovation Access,
National Institute of Dental and
Craniofacial Research on or before July
9, 2018 will be considered.
ADDRESSES: Requests for copies of the
patent application, inquiries, and
comments relating to the contemplated
an Exclusive Patent License should be
directed to: Yun Mei, Technology
Transfer and Patent Specialist, Office of
Technology Transfer and Innovation
Access, National Institute of Dental and
Craniofacial Research, National
Institutes of Health, BLDG 1 DEM,
RM667, 6701 Democracy Blvd.,
Bethesda, MD 20817; Telephone: (301)
827–4639; Facsimile: (301) 496–1005;
Email: yun.mei@nih.gov.
SUPPLEMENTARY INFORMATION:
daltland on DSKBBV9HB2PROD with NOTICES
SUMMARY:
Intellectual Property
1. U.S. Provisional Patent Application
No. 61/885,258, filed October 1, 2013
and entitled ‘‘Methods of Modulating
Erythropoiesis with Arginine
Vasopressin Receptor 1B Molecules’’
VerDate Sep<11>2014
17:16 Jun 21, 2018
Jkt 244001
(HHS Reference No. E–619–2013–0–US–
01);
2. PCT Application No. PCT/US2014/
058613, filed October 1, 2014 and
entitled ‘‘Methods of Modulating
Erythropoiesis with Arginine
Vasopressin Receptor 1B Molecules’’
(HHS Reference No. E–619–2013–0–
PCT–02);
3. U.S. Patent Application No. 15/
022,531, filed March 16, 2016 and
entitled ‘‘Methods of Modulating
Erythropoiesis with Arginine
Vasopressin Receptor 1B Molecules’’
(HHS Reference No. E–619–2013–0–US–
03);
The patent rights in these inventions
have been assigned and/or exclusively
licensed to the government of the
United States of America.
The prospective exclusive license
territory may be the United States and
the field of use may be limited to ‘‘Use
of arginine vasopressin receptor 1B
agonists to treat anemia caused by (i)
chronic renal failure on dialysis, (ii)
receiving myelosuppressive
chemotherapy, or (iii) lacking
antidiuretic hormone.’’
The subject technology is a method of
using arginine vasopressin receptor 1B
(AVPR1B) agonists to increase the
number of red blood cells to treat
anemia. The inventors discovered that
hematopoietic stem cells express
AVPR1B receptor, and these receptors
play a key role in promoting
hematopoietic stem and progenitor cell
proliferation. The number of red blood
cells and their precursors significantly
increased on day 2 following
vasopressin administration, an onset
time much faster than erythropoietin
(EPO), which is commonly used to
stimulate red blood cell production for
anemia treatment. EPO takes about a
week to manifest its clinical effects. The
AVPR1B agonists can be used to
jumpstart the hematopoietic system and
erythropoietin can be used to sustain
the effect.
The subject technology is a
repurposing of an existing drug,
vasopressin, an AVPR1B agonist, also
called antidiuretic hormone. It is a nineamino acid peptide secreted from the
posterior pituitary and used to treat
patients with central diabetes insipidus,
an uncommon disorder that causes an
imbalance of water in the body. This
imbalance leads to excretion of large
amount of urine (polyuria) and intense
thirst even after drinking fluids
(polydipsia).
This notice is made in accordance
with 35 U.S.C. 209 and 37 CFR part 404.
The prospective exclusive license will
be royalty bearing, and the prospective
exclusive license may be granted unless
PO 00000
Frm 00040
Fmt 4703
Sfmt 4703
29127
within fifteen (15) days from the date of
this published notice, the National
Institute of Dental and Craniofacial
Research receives written evidence and
argument that establishes that the grant
of the license would not be consistent
with the requirements of 35 U.S.C. 209
and 37 CFR part 404.
In response to this Notice, the public
may file comments or objections.
Comments and objections, other than
those in the form of a license
application, will not be treated
confidentially, and may be made
publicly available.
License applications submitted in
response to this Notice will be
presumed to contain business
confidential information and any release
of information in these license
applications will be made only as
required and upon a request under the
Freedom of Information Act, 5 U.S.C.
552.
Dated: June 19, 2018.
David W. Bradley,
Director, Office of Technology Transfer and
Innovation Access, National Institute of
Dental and Craniofacial Research, National
Institutes of Health.
[FR Doc. 2018–13443 Filed 6–21–18; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions;
Availability for Licensing
AGENCY:
National Institutes of Health,
HHS.
ACTION:
Notice.
The invention listed below is
owned by an agency of the U.S.
Government and is available for
licensing to achieve expeditious
commercialization of results of
federally-funded research and
development. Foreign patent
applications are filed on selected
inventions to extend market coverage
for companies and may also be available
for licensing.
FOR FURTHER INFORMATION CONTACT: Dr.
Barry Buchbinder, 240–627–3678;
barry.buchbinder@nih.gov. Licensing
information and copies of the U.S.
patent application listed below may be
obtained by communicating with the
indicated licensing contact at the
Technology Transfer and Intellectual
Property Office, National Institute of
Allergy and Infectious Diseases, 5601
Fishers Lane, Rockville, MD 20852; tel.
301–496–2644. A signed Confidential
SUMMARY:
E:\FR\FM\22JNN1.SGM
22JNN1
]]>Agencies
[Federal Register Volume 83, Number 121 (Friday, June 22, 2018)]
[Notices]
[Pages 29126-29127]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2018-13419]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Office of the Director, National Institutes of Health; Notice of
Meeting
Pursuant to section 10(a) of the Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is hereby given of a meeting of the
Office of AIDS Research Advisory Council.
The meeting will be open to the public, with attendance limited to
space available. Individuals who plan to attend and need special
assistance, such as sign language interpretation or other reasonable
accommodations, should notify the Contact Person listed below in
advance of the meeting.
Name of Committee: Office of AIDS Research Advisory Council.
Date: July 12, 2018.
Time: 11:00 a.m. to 12:30 p.m.
Agenda: Report to the OAR Director; Overview of key upcoming OAR
activities; Updates of the HHS HIV/AIDS Treatment and Prevention
Guidelines.
Place: National Institutes of Health, 5601 Fishers Lane,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Paul A. Sato, Medical Officer, Office of AIDS
Research, Office of the Director, NIH, 5601 Fishers Lane, Room 2E62
Rockville, MD 20852, 240-480-2330, [email protected].
Any interested participants are encouraged to join this meeting
at the weblink provided, at least 30 minutes prior to the scheduled
start time. Information is also available on the Institute's/
Center's home page: www.oar.nih.gov, where an agenda and any
additional information for the meeting will be posted when
available.
(Catalogue of Federal Domestic Assistance Program Nos. 93.14,
Intramural Research Training Award; 93.22, Clinical Research Loan
Repayment Program for Individuals from Disadvantaged Backgrounds;
93.232, Loan Repayment Program for Research Generally; 93.39,
Academic Research
[[Page 29127]]
Enhancement Award; 93.936, NIH Acquired Immunodeficiency Syndrome
Research Loan Repayment Program; 93.187, Undergraduate Scholarship
Program for Individuals from Disadvantaged Backgrounds, National
Institutes of Health, HHS)
Dated: June 19, 2018.
Natasha M. Copeland,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2018-13419 Filed 6-21-18; 8:45 am]
BILLING CODE 4140-01-P
